![\"\"](\"https:\/\/jacksangelsfoundation.com\/wp-content\/uploads\/2021\/03\/logo-bexion-1.png\"){kind=logo}
<\/p>\n<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
Today on Childhood Cancer Talk Radio on TogiNet.com at 4pm EST,\u00a0 Founder and CEO of Bexion Pharmaceuticals Dr. Ray Takigiku and Medical Affairs Consultant and Leader of the phase II clinical trial for DIPG\/DMG at Cincinnati Children’s Hospital,<\/p>\n
![\"\"](\"https:\/\/jacksangelsfoundation.com\/wp-content\/uploads\/2021\/03\/DrCurry-pic-150x150.png\")
Dr. Richard C. Curry III<\/p><\/div>\n
Dr. Richard Curry.\u00a0 Both scientists provide insight into the discovery and development of this drug and their hopes for its success in the trial for BXQ-350, Bexion’s lead drug candidate, a first-in-class biologic containing the multifunctional, lysosomal activator protein Saposin C and a phosphatidylserine.<\/p>\n
BXQ-350 has demonstrated pre-clinical anti-tumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.\u00a0 Bexion has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas.\u00a0 Bexion is in Phase 2 for DIPG\/DMG and plans to initiate two adult Phase 2 programs in 2021.\u00a0 Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in CNS diseases including peripheral neuropathy.<\/p>\n
<\/p>\n
FOR IMMEDIATE RELEASE<\/a> Covington, KY, December 10, 2020\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/em><\/p>\n Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome\u2019s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the\u00a0Phase 1 study of\u00a0BXQ-350\u00a0in adult patients with advanced solid tumors<\/a>. Bexion presented interim results from this study at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting in June.<\/p>\n The phase 1 trial of BXQ-350 was conducted at the Ohio State University Comprehensive Cancer Center, the University of Cincinnati Barrett Center, the University of Kentucky Markey Cancer Center and the University of New Mexico Cancer Center. The study enrolled 86 patients, who had failed prior therapies with over 20 types of advanced solid tumors, including 20 patients with Glioblastoma Multiforme (GBM). BXQ-350 exhibited a very strong safety and tolerability profile with no Dose Limiting Toxicities (DLTs) and only 1 Grade 4 Serious Adverse Event (SAE), which was resolved. Two GBM patients and one Colorectal patient have been moved to a long-term trial, continuing on BXQ-350.<\/p>\n \u201cWe are thrilled to reach this milestone and are looking forward to processing and analyzing this trial data\u201d said Dr. Ray Takigiku, PhD, President and CEO at Bexion Pharmaceuticals.\u00a0 \u201cWe are further excited to continue to pursue our Phase 2 studies in DIPG\/DMG as previously announced, and two others to be announced in 2021\u201d.<\/p>\n Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein, Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.\u00a0\u00a0 Bexion has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas. Database lock on Bexion\u2019s Phase 1 Pediatric Trial was completed earlier this year.<\/p>\nAbout Bexion Pharmaceuticals<\/h2>\n